146 related articles for article (PubMed ID: 35031387)
1. Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy.
Li J; Zhao M; Liang W; Wu S; Wang Z; Wang D
J Control Release; 2022 Feb; 342():308-320. PubMed ID: 35031387
[TBL] [Abstract][Full Text] [Related]
2. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
3. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment.
Li J; Zhao M; Sun M; Wu S; Zhang H; Dai Y; Wang D
ACS Appl Mater Interfaces; 2020 Nov; 12(45):50734-50747. PubMed ID: 33124808
[TBL] [Abstract][Full Text] [Related]
5. A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation.
Luo K; Yang L; Yan C; Zhao Y; Li Q; Liu X; Xie L; Sun Q; Li X
Small; 2023 Oct; 19(40):e2302834. PubMed ID: 37264710
[TBL] [Abstract][Full Text] [Related]
6. Shikonin and chitosan-silver nanoparticles synergize against triple-negative breast cancer through RIPK3-triggered necroptotic immunogenic cell death.
Liang J; Tian X; Zhou M; Yan F; Fan J; Qin Y; Chen B; Huo X; Yu Z; Tian Y; Deng S; Peng Y; Wang Y; Liu B; Ma X
Biomaterials; 2024 Sep; 309():122608. PubMed ID: 38744189
[TBL] [Abstract][Full Text] [Related]
7. Hybrid micelles codelivering shikonin and IDO-1 siRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment.
Li J; Zhao M; Xu Y; Hu X; Dai Y; Wang D
Int J Pharm; 2021 Mar; 597():120310. PubMed ID: 33540035
[TBL] [Abstract][Full Text] [Related]
8. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
[TBL] [Abstract][Full Text] [Related]
10. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death.
Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H
Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008
[TBL] [Abstract][Full Text] [Related]
11. Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1.
Wang H; Tang Y; Fang Y; Zhang M; Wang H; He Z; Wang B; Xu Q; Huang Y
Nano Lett; 2019 May; 19(5):2935-2944. PubMed ID: 30950276
[TBL] [Abstract][Full Text] [Related]
12. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
13. A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer.
Yao D; Wang Y; Bian K; Zhang B; Wang D
Biomaterials; 2023 Jan; 292():121920. PubMed ID: 36442436
[TBL] [Abstract][Full Text] [Related]
14. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer.
Qiu X; Qu Y; Guo B; Zheng H; Meng F; Zhong Z
J Control Release; 2022 Jan; 341():498-510. PubMed ID: 34883139
[TBL] [Abstract][Full Text] [Related]
15. TGF-β blockade-improved chemo-immunotherapy with pH/ROS cascade-responsive micelle via tumor microenvironment remodeling.
Dai L; Li X; Zheng X; Fu Z; Yao M; Meng S; Zhang J; Han B; Gao Q; Chang J; Cai K; Yang H
Biomaterials; 2021 Sep; 276():121010. PubMed ID: 34247042
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Mitochondrial Biosynthesis Using a "Right-Side-Out" Membrane-Camouflaged Micelle to Facilitate the Therapeutic Effects of Shikonin on Triple-Negative Breast Cancer.
Peng J; Hu X; Fan S; Zhou J; Ren S; Sun R; Chen Y; Shen X; Chen Y
Adv Healthc Mater; 2022 Sep; 11(18):e2200742. PubMed ID: 35818932
[TBL] [Abstract][Full Text] [Related]
17. Homotypic targeted nanoplatform enable efficient chemoimmunotherapy and reduced DOX cardiotoxicity in chemoresistant cancer via TGF-β1 blockade.
Li N; Zhang T; Wang R; Sun Y; Chu L; Lu X; Sun K
J Control Release; 2023 Sep; 361():147-160. PubMed ID: 37536544
[TBL] [Abstract][Full Text] [Related]
18. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
[TBL] [Abstract][Full Text] [Related]
19. Photosensitive small extracellular vesicles regulate the immune microenvironment of triple negative breast cancer.
Ding YN; Ding HY; Li H; Yang R; Huang JY; Chen H; Wang LH; Wang YJ; Hu CM; An YL; Zhang ZY; Yu WP; Tang QS; Shao GL
Acta Biomater; 2023 Sep; 167():534-550. PubMed ID: 37302734
[TBL] [Abstract][Full Text] [Related]
20. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy.
Shi M; Zhang J; Wang Y; Han Y; Zhao X; Hu H; Qiao M; Chen D
Acta Biomater; 2022 Sep; 150():353-366. PubMed ID: 35843594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
